Targets › EP300
2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Dec 2027.
Functions as a histone acetyltransferase and regulates transcription via chromatin remodeling. Acetylates all four core histones in nucleosomes. (UniProt, Q09472)
Open in Phaseline: the race on EP300, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Opna Bio | OPN-6602 EP300 and CBP bromodomain inhibitor | EP300, CBP | Phase 1 | Relapsed Multiple Myeloma | Dec 2027 |
| Pathos AI | Pocenbrodib Selective oral inhibitor of CBP/p300 bromodomain interaction with acetylated lysines on hi | CREBBP, EP300 | Phase 1 | mCRPC (Metastatic Castration-resistant Prostate Cancer) | Jun 2028 |
Relapsed Multiple Myeloma (1) mCRPC (Metastatic Castration-resistant Prostate Cancer) (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.